Found: 31
Select item for more details and to access through your institution.
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.
- Published in:
- Journal of Clinical Medicine, 2019, v. 8, n. 10, p. 1695, doi. 10.3390/jcm8101695
- By:
- Publication type:
- Article
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network.
- Published in:
- Journal of Clinical Medicine, 2019, v. 8, n. 6, p. 877, doi. 10.3390/jcm8060877
- By:
- Publication type:
- Article
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 7, p. E157, doi. 10.1002/ajh.26927
- By:
- Publication type:
- Article
Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs.
- Published in:
- Cancers, 2024, v. 16, n. 15, p. 2732, doi. 10.3390/cancers16152732
- By:
- Publication type:
- Article
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities.
- Published in:
- Cancers, 2021, v. 13, n. 13, p. 3213, doi. 10.3390/cancers13133213
- By:
- Publication type:
- Article
Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 6, p. 860, doi. 10.1111/ejh.14181
- By:
- Publication type:
- Article
Teclistamab‐cqyv in multiple myeloma.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 320, doi. 10.1111/ejh.14121
- By:
- Publication type:
- Article
Iron chelation therapy.
- Published in:
- European Journal of Haematology, 2023, v. 110, n. 5, p. 490, doi. 10.1111/ejh.13935
- By:
- Publication type:
- Article
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
- Published in:
- European Journal of Haematology, 2022, v. 108, n. 3, p. 178, doi. 10.1111/ejh.13723
- By:
- Publication type:
- Article
Validation of the Alternative International Prognostic Score‐E (AIPS‐E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O‐CLL1‐GISL protocol.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 6, p. 831, doi. 10.1111/ejh.13614
- By:
- Publication type:
- Article
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.684621
- By:
- Publication type:
- Article
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.643490
- By:
- Publication type:
- Article
Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity.
- Published in:
- Journal of Translational Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12967-024-05013-0
- By:
- Publication type:
- Article
Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.
- Published in:
- Chemotherapy (0009-3157), 2019, v. 64, n. 2, p. 110, doi. 10.1159/000502473
- By:
- Publication type:
- Article
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
Diplopia and hemianopsia as initial manifestations of multicentric Castleman disease successfully treated with siltuximab.
- Published in:
- Current Therapeutics, 2022, v. 25, n. 5, p. 20
- By:
- Publication type:
- Article
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.
- Published in:
- Drug Design, Development & Therapy, 2021, v. 15, p. 2969, doi. 10.2147/DDDT.S295215
- By:
- Publication type:
- Article
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 4, p. 1, doi. 10.1002/hon.3290
- By:
- Publication type:
- Article
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 1, p. 1, doi. 10.1002/hon.3249
- By:
- Publication type:
- Article
Tagraxofusp in myeloid malignancies.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 1, p. 1, doi. 10.1002/hon.3234
- By:
- Publication type:
- Article
Myelodysplastic syndromes with ring sideroblasts.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 4, p. 612, doi. 10.1002/hon.3125
- By:
- Publication type:
- Article
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 1009, doi. 10.1002/hon.3035
- By:
- Publication type:
- Article
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 4, p. 704, doi. 10.1002/hon.3031
- By:
- Publication type:
- Article
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study.
- Published in:
- Non-Coding RNA, 2024, v. 10, n. 5, p. 46, doi. 10.3390/ncrna10050046
- By:
- Publication type:
- Article
Measurable therapeutic antibody in serum as potential predictive factor of response to anti-CD38 therapy in non-IgG-k myeloma patients.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.890376
- By:
- Publication type:
- Article
Tsukamurella tyrosinosolvens Intravascular Catheter Infection Identified Using 16S Ribosomal DNA Sequencing.
- Published in:
- Clinical Infectious Diseases, 2003, v. 36, n. 5, p. e69, doi. 10.1086/367654
- By:
- Publication type:
- Article
Correction: Antonuccio et al. The Nutraceutical N-Palmitoylethanolamide (PEA) Reveals Widespread Molecular Effects Unmasking New Therapeutic Targets in Murine Varicocele. Nutrients 2021, 13 , 734.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
The Nutraceutical N-Palmitoylethanolamide (PEA) Reveals Widespread Molecular Effects Unmasking New Therapeutic Targets in Murine Varicocele.
- Published in:
- Nutrients, 2021, v. 13, n. 3, p. 734, doi. 10.3390/nu13030734
- By:
- Publication type:
- Article